<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995721</url>
  </required_header>
  <id_info>
    <org_study_id>50934</org_study_id>
    <nct_id>NCT01995721</nct_id>
  </id_info>
  <brief_title>4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children</brief_title>
  <official_title>Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Child Health, Hungary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Child Health, Hungary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent respiratory papillomatosis in children caused by HPV 6,11 can be a life threatening
      condition resulting in surgical interventions. The maturing and disintegrating papillomas are
      the sources for the subsequent HPV relapses and immunization might slow down or even prevent
      this ongoing process.

      After an initial immunological and ear-nose-throat (ENT) assessment children with at least 3
      relapses in their patient history will be vaccinated with 4-valent HPV vaccine according to
      the following schedule: 0., 2., 6. months. It will be followed by an immunological and 3 ENT
      examinations to assess response to vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Enrollment

             -  ear-nose-throat (ENT) examination + oesophagoscopy

             -  immunological assessment

                  -  assessment of selected humoral (antibodies) and

                  -  cellular immune response parameters(INF gamma and granzyme B testing)

                  -  in vitro and in vivo stimulation of PMBCs with the HPV-4 vaccine

        2. Immunization with 4-valent HPV vaccine at 0,2,6 months

        3. Follow up

             -  1 month after 3rd vaccine dose - immunological assessment (same tests as in the
                enrollment phase)

             -  6, 12 and 18 months after the 3rd vaccine dose - ENT + oesophagoscopy
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Papilloma relapses</measure>
    <time_frame>18 months after the 3rd vaccine</time_frame>
    <description>Number of relapses and surgical treatment needed after the 3rd vaccine dose during the 18--months follow-up period</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Recurrent Respiratory Papillomatosis</condition>
  <arm_group>
    <arm_group_label>4-valent HPV vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-valent HPV vaccine administered in months 0., 2., 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4-valent HPV vaccine</intervention_name>
    <description>Vaccination with 4-valent HPV vaccine in months 0., 2., 6.</description>
    <arm_group_label>4-valent HPV vaccine</arm_group_label>
    <other_name>Silgard</other_name>
    <other_name>Gardasil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  respiratory papillomatosis

          -  at least 3 relapses in patient history

          -  HPV 6 and/or 11 positive papillomas

          -  able to mount neutralizing antibodies

        Exclusion Criteria:

          -  other chronic underlying condition

          -  other HPV type

          -  no antibody response
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zsofia Meszner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Child Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zsofia Meszner, MD, PhD</last_name>
    <phone>+36 1 365 1540</phone>
    <email>zmeszner@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Child Health</name>
      <address>
        <city>Budapest</city>
        <zip>1113</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zsofia Meszner</last_name>
      <phone>+36 1 365-1540</phone>
      <email>zmeszner@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Zsofia Meszner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Child Health, Hungary</investigator_affiliation>
    <investigator_full_name>dr. med habil Zs√≥fia Meszner PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>recurrent respiratory papillomatosis</keyword>
  <keyword>human papillomavirus</keyword>
  <keyword>vaccine</keyword>
  <keyword>treatment</keyword>
  <keyword>immunology</keyword>
  <keyword>relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

